RÉSUMÉ
pUDK-HGF, the recombinant plasmid DNA encoding human hepatocyte growth factor (HGF), can treat ischaemic disease. A great quantity of pharmaceutical pUDK-HGF is needed. A pilot-scale production process of pUDK-HGF was established based on a new chromatographic media (plasmidselect), including fermentation, cell harvesting, alkaline lysis, ultrafiltration, RNA removing and buffer exchanging on Sephacryl S-1000, capturing supercoiled plasmid DNA with plasmidselect, and removing the salt with Sepharose 6BFF. The process does not use RNase enzyme and toxic solvents.
Sujet(s)
Humains , ADN recombiné , ADN superhélicoïdal , Escherichia coli , Génétique , Métabolisme , Fermentation , Vecteurs génétiques , Génétique , Facteur de croissance des hépatocytes , Génétique , Projets pilotes , PlasmidesRÉSUMÉ
OBJECTIVE@#To evaluate the clinical therapeutic effect of Rabdosia rubescens aqueous extract on chronic pharyngitis and its safety.@*METHODS@#One hundred and two patients suffered from chronic pharyngtis were randomly divided into an interventional group (n=51) and a placebo group (n=51). These volunteers were given 220 mL test materials once a day double-blindly for 30 days. All patients took routine physical examinations, and their throat symptom and pharynx signs were observed before and after the experiment.@*RESULTS@#After the patients had consumed Rabdosia rubescens aqueous extract and the placebo for 30 days, the improvement rates of main clinical symptom and signs in the interventional group were 67.31% and 61.54%, while those in placebo group were 19.23% and 11.54%, with significant difference (P0.05). But after 30 days, the integral of main clinical symptom and signs in the interventional group significantly decreased (P<0.05), compared with itself before the experiment and the placebo group.@*CONCLUSION@#Rabdosia rubescens aqueous extract is safe and effective for patients with chronic pharyngitis.